Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00783341 | Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously | PHASE1 | COMPLETED | 25 | — | — | Nov 1, 2008 | Feb 1, 2009 | Jul 17, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| GAP-134 | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GAP-134 | DRUG | - |
| placebo | DRUG | - |
Inclusion 1. Men or women of non childbearing potential (WONCBP) aged 18 to 50 years inclusive at screening. 2. Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ≥50 kg. 3. Healthy as determined by the investigator on the basis of medical history, physical examination, clinic...